ASX:CUVBiotechs
How Investors Are Reacting To Clinuvel Pharmaceuticals (ASX:CUV) EMA Guidance On SCENESSE Vitiligo Trial Design
Clinuvel Pharmaceuticals recently reported that the European Medicines Agency issued final scientific advice on its planned pivotal Phase III CUV107 trial, outlining how SCENESSE (afamelanotide) will be evaluated as a systemic treatment for non-segmental vitiligo in adults and adolescents.
The regulator’s “totality of evidence” approach, with T-VASI50 as the primary endpoint and strong emphasis on patient-reported and photographic outcomes, underscores both the complexity and patient-centric...